Platelet and Blood Vessel Disorders

Published on 27/03/2015 by admin

Filed under Pediatrics

Last modified 27/03/2015

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 2421 times

Chapter 478 Platelet and Blood Vessel Disorders


Platelets are non-nucleated cellular fragments produced by megakaryocytes within the bone marrow and other tissues. Megakaryocytes are large polyploid cells. When the megakaryocyte approaches maturity, budding of the cytoplasm occurs and large numbers of platelets are liberated. Platelets circulate with a life span of 10-14 days. Thrombopoietin (TPO) is the primary growth factor that controls platelet production (Fig. 478-1). Levels of TPO appear to correlate inversely with platelet number and megakaryocyte mass. Levels of TPO are highest in the thrombocytopenic states associated with decreased marrow megakaryopoiesis and may be variable in states of increased platelet production.

The platelet plays multiple hemostatic roles. The platelet surface possesses a number of important receptors for adhesive proteins, including von Willebrand factor (VWF) and fibrinogen, as well as receptors for agonists that trigger platelet aggregation, such as thrombin, collagen, and adenosine diphosphate (ADP). After injury to the blood vessel wall, subendothelial collagen binds VWF. VWF undergoes a conformational change that induces binding of the platelet glycoprotein Ib (GPIb) complex (the VWF receptor). This process is called platelet adhesion. Platelets then undergo activation. During the process of activation, the platelets generate thromboxane A2 from arachidonic acid via the enzyme cyclo-oxygenase. After activation, platelets release agonists, such as ADP, adenosine triphosphate (ATP), Ca2+, serotonin, and coagulation factors, into the surrounding milieu. Binding of VWF to the GPIb complex triggers a complex signaling cascade that results in activation of the fibrinogen receptor, the major platelet integrin glycoprotein αIIb3 (GPIIb-IIIa). Circulating fibrinogen binds to its receptor on the activated platelets, complex linking platelets together in a process called aggregation. This series of events forms a hemostatic plug at the site of vascular injury. The serotonin and histamine that are liberated during activation increase local vasoconstriction. In addition to acting in concert with the vessel wall to form the platelet plug, the platelet provides the catalytic surface on which coagulation factors assemble and eventually generate thrombin through a sequential series of enzymatic cleavages. Last, the platelet contractile proteins and cytoskeleton mediate clot retraction.


The normal platelet count is 150-450 × 109/L. Thrombocytopenia refers to a reduction in platelet count to <150 × 109/L. Causes of thrombocytopenia include: (1) decreased production on either a congenital or an acquired basis; (2) sequestration of the platelets within an enlarged spleen or other organ; and (3) increased destruction of normally synthesized platelets on either an immune or a nonimmune basis (Chapter 469; Tables 478-1 and 478-2 and Fig. 478-2).



Primary Platelet Consumption Syndromes

Combined Platelet and Fibrinogen Consumption Syndromes



HIV, human immunodeficiency virus; ITP, immune thrombocytopenic purpura; VWD, von Willebrand disease.

From Wilson DB: Acquired platelet defects. In Orkin SH, Nathan DG, Ginsburg D, et al, editors: Nathan and Oski’s hematology of infancy and childhood, ed 7, Philadelphia, 2009, WB Saunders, p 1555, Box 33-1.


Fetal Alloimmune thrombocytopenia
Congenital infection (e.g., CMV, toxoplasma, rubella, HIV)
Aneuploidy (e.g., trisomy 18, 13, or 21, or triploidy)
Autoimmune condition (e.g., ITP, SLE)
Severe Rh hemolytic disease
Congenital/inherited (e.g., Wiskott-Aldrich syndrome)
Early-onset neonatal (<72 hr) Placental insufficiency (e.g., PET, IUGR, diabetes)
Perinatal asphyxia
Perinatal infection (e.g., Escherichia coli, GBS, Haemophilus influenzae)
Alloimmune thrombocytopenia
Autoimmune condition (e.g., ITP, SLE)
Congenital infection (e.g., CMV, toxoplasma, rubella, HIV)
Thrombosis (e.g., aortic, renal vein)
Bone marrow replacement (e.g., congenital leukemia)
Kasabach-Merritt syndrome
Metabolic disease (e.g., proprionic and methylmalonic acidemia)
Congenital/inherited (e.g., TAR, CAMT)
Late-onset neonatal (>72 hr) Late-onset sepsis
Congenital infection (e.g., CMV, toxoplasma, rubella, HIV)
Kasabach-Merritt syndrome
Metabolic disease (e.g., proprionic and methylmalonic acidemia)
Congenital/inherited (e.g., TAR, CAMT)

CAMT, congenital amegakaryocytic thrombocytopenia; CMV, cytomegalovirus; DIC, disseminated intravascular coagulation; GBS, group B streptococcus; ITP, idiopathic thrombocytopenic purpura; IUGR, intrauterine growth restriction; NEC, necrotizing enterocolitis; PET, preeclampsia; SLE, systemic lupus erythematosus; TAR, thrombocytopenia with absent radii.

* The most common conditions are shown in bold.

From Roberts I, Murray NA: Neonatal thrombocytopenia: causes and management, Arch Dis Child Fetal Neonatal Ed 88:F359–F364, 2003.

478.1 Idiopathic (Autoimmune) Thrombocytopenic Purpura

The most common cause of acute onset of thrombocytopenia in an otherwise well child is (autoimmune) idiopathic thrombocytopenic purpura (ITP).

Clinical Manifestations

The classic presentation of ITP is a previously healthy 1-4 yr old child who has sudden onset of generalized petechiae and purpura. The parents often state that the child was fine yesterday and now is covered with bruises and purple dots. Often there is bleeding from the gums and mucous membranes, particularly with profound thrombocytopenia (platelet count <10 × 109/L). There is a history of a preceding viral infection 1-4 wk before the onset of thrombocytopenia. Findings on physical examination are normal, other than the finding of petechiae and purpura. Splenomegaly, lymphadenopathy, bone pain, and pallor are rare. An easy to use classification system has been proposed from the U.K. to characterize the severity of bleeding in ITP on the basis of symptoms and signs, but not platelet count:

The presence of abnormal findings such as hepatosplenomegaly, bone or joint pain, or remarkable lymphadenopathy suggests other diagnoses (leukemia). When the onset is insidious, especially in an adolescent, chronic ITP or the possibility of a systemic illness, such as systemic lupus erythematosus (SLE), is more likely.

Laboratory Findings

Severe thrombocytopenia (platelet count <20 × 109/L) is common, and platelet size is normal or increased, reflective of increased platelet turnover (Fig. 478-3). In acute ITP, the hemoglobin value, white blood cell (WBC) count, and differential count should be normal. Hemoglobin may be decreased if there have been profuse nosebleeds or menorrhagia. Bone marrow examination shows normal granulocytic and erythrocytic series, with characteristically normal or increased numbers of megakaryocytes. Some of the megakaryocytes may appear to be immature and are reflective of increased platelet turnover. Indications for bone marrow aspiration/biopsy include an abnormal WBC count or differential or unexplained anemia as well as findings on history and physical examination suggestive of a bone marrow failure syndrome or malignancy. Other laboratory tests should be performed as indicated by the history and physical examination. In adolescents with new-onset ITP, an antinuclear antibody test should be done to evaluate for SLE. HIV studies should be done in at-risk populations, especially sexually active teens. Platelet antibody testing is seldom useful in acute ITP. A direct antiglobulin test (Coombs) should be done if there is unexplained anemia to rule out Evans syndrome (autoimmune hemolytic anemia and thrombocytopenia) (Chapter 458) or before instituting therapy with IV anti-D.


Figure 478-3 Blood smear and bone marrow aspirate from a child who had ITP showing large platelets (blood smear [left]) and increased numbers of megakaryocytes, many of which appear immature (bone marrow aspirate [right]).

(From Blanchette V, Bolton-Maggs P: Childhood immune thrombocytopenic purpura: diagnosis and management, Pediatr Clin North Am 55:393–420, 2008, p 400, Fig 4.)

Diagnosis/Differential Diagnosis

The well-appearing child with moderate to severe thrombocytopenia, an otherwise normal complete blood cell count (CBC), and normal findings on physical examination has a limited differential diagnosis that includes exposure to medication that induces drug-dependent antibodies, splenic sequestration due to previously unappreciated portal hypertension, and rarely, early aplastic processes, such as Fanconi anemia (Chapter 462). Other than congenital thrombocytopenia syndromes (Chapter 478.8), such as thrombocytopenia-absent radius (TAR) syndrome and MYH9-related thrombocytopenia, most marrow processes that interfere with platelet production eventually cause abnormal synthesis of red blood cells (RBCs) and WBCs and therefore manifest diverse abnormalities on the CBC. Disorders that cause increased platelet destruction on a nonimmune basis are usually serious systemic illnesses with obvious clinical findings (e.g., hemolytic-uremic syndrome [HUS], disseminated intravascular coagulation [DIC]) [see Table 477-1 and Fig. 478-2]. Isolated enlargement of the spleen suggests the potential for hypersplenism owing to either liver disease or portal vein thrombosis. Autoimmune thrombocytopenia may be an initial manifestation of SLE, HIV infection, common variable immunodeficiency, or rarely lymphoma. Wiskott-Aldrich syndrome (WAS; Chapter 120.2) must be considered in young males found to have thrombocytopenia with small platelets, particularly if there is a history of eczema and recurrent infection.


Buy Membership for Pediatrics Category to continue reading. Learn more here